Additional Efficacy Data Support Selection of Pilavapadin 10mg for Phase Three Development in DPNP: Results From PROGRESS (S38.005)

Suma Gopinathan; Craig Granowitz; MARQUETTE HARDIN; P Banks; PHILLIP PIERCE; Manon Girard

doi:10.1212/wnl.0000000000217348

June 9, 2026Neurology

Additional Efficacy Data Support Selection of Pilavapadin 10mg for Phase Three Development in DPNP: Results From PROGRESS (S38.005)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to determine the efficacy of pilavapadin 10 mg for treating diabetic peripheral neuropathic pain.
Conducted the PROGRESS trial evaluating different doses of pilavapadin.
Focused on identifying the dose with optimal efficacy for Phase 3 development.
Pilavapadin 10 mg showed significant efficacy compared to lower doses in relieving pain.
Efficacy outcomes warrant selection of the 10 mg dose for further Phase 3 trials.

Implication

Demonstrates efficacy of pilavapadin 10 mg in diabetic peripheral neuropathic pain, supporting its Phase 3 development.

Abstract

To present PROGRESS efficacy supporting selection of pilavapadin 10 mg as the optimal dose for Phase 3 in diabetic peripheral neuropathic pain (DPNP).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gopinathan et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f0562ae https://doi.org/10.1212/wnl.0000000000217348

View at Publisher

Ask AI

Bookmark

Share

Additional Efficacy Data Support Selection of Pilavapadin 10mg for Phase Three Development in DPNP: Results From PROGRESS (S38.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Additional Efficacy Data Support Selection of Pilavapadin 10mg for Phase Three Development in DPNP: Results From PROGRESS (S38.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology